Evaluation of cerebrospinal fluid for the presence of anticardiolipin antibodies (aCL) in NP-SLE patients

Clinical Rheumatology

Volumn 19, Issue 4, 2000, Pages 306-310

  Jedryka Goral A ^a   Zabek J ^b   Wojciechowska, B ^b   Zaborski, J ^c   Chwalinska Sadowska H ^a   Czlonkowska A ^c  

^a Department of Connective Tissue Diseases ^*  (Poland)

^b INSTITUTE OF RHEUMATOLOGY   (Poland)

^c INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

ACL; Cerebrospinal fluid; Systemic lupus erythematosus

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGLOBULIN PRODUCTION; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0033854018     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100670070051     Document Type: Article

References (31)

1. Antiphospholipid syndrome within systemic lupus erythematosus
2. Anticardiolipin antibodies: Clinical characteristics of antibody positive patients with recent cerebrovascular events
3. Clinical manifestations and management of the antiphospholipid syndrome
4. Neuropsychiatric lupus erythematosus cerebral infractions and anticardiolipin
5. Neurological and obstetric manifestations of the antiphospholipid syndrome
6. Cerebrospinal fluid
7. Anticardiolipin antibodies detected by a new solid phase radioimmunoassay: Striking association with thrombosis
8. Inhibition of astrocyte proliferation and binding to brain tissue of anticardiolipin antibodies purified from lupus serum
9. Neurological dysfunction and hyperactive behaviour associated with antiphospholipid antibodies. A mouse model
10. Revised criteria for the classification of systemic lupus erythematosus
11. An improved formula for judgment of intrathecally produced IgG in the presence of blood brain barrier damage
12. The discrimination between different blood-CSF barrier dysfunctions and inflammatory reactions of the CNS by recent evaluation graph for the protein profile of cerebrospinal fluid
13. Multiple sclerosis: The blood-brain barrier and the measurement of de novo central nervous IgG synthesis
14. Detection of oligoclonal IgG bands in cerebrospinal fluid in multiple sclerosis and other neurological diseases using Phast system. Correspondence with magnetic resonance imaging changes
15. Detection of oligoclonal IgG bands in cerebrospinal fluid by immunofixation after isoelectric focusing on polyacrylamide gels with Phast system
16. Anticardiolipin antibodies: Isotype distribution and phospholipid specificity
17. 2 glicoprotein I in the rat: Isolation from serum and demonstration in lipoprotein density fractions
18. Protein measurement with Folin phenol reagent
19. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement
20. Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erthematosus, and Behcet's disease involving the nervous system
21. Autoantibodies in the cerebrospinal fluid of patients with systemic lupus erthematosus
22. Anticardiolipin antibodies and interleukin-6 in cerebrospinal fluid and blood of Chinese patients with neuro-Behcet's syndrome
23. Cerebrospinal fluid and serum antiphospholipid antibodies in multiple sclerosis, Guillain-Barre syndrome and systemic lupus erythematosus
24. Anticardiolipin antibodies in serum and cerebrospinal fluid from patients with systemic lupus erythematosus
25. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to plasma protein cofactor
26. Anticardiolipin antibodies and lupus anticoagulants comprise antibody subgroups with different phospholipid binding characteristics
27. 2-Glycoprotein I (apolipoprotein H)